Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.
复制标题

组蛋白脱乙酰基酶1、2和3在前列腺癌中高度表达,而HDAC2表达与前列腺癌后psa的PSA复发时间较短有关。

DOI:
10.1038/sj.bjc.6604199
复制
发表时间:
2008-02-12
影响因子:
8.8
通讯作者:
Kristiansen, G.
Kristiansen, G.
中科院分区:
医学1区
文献类型:
--
作者:
Weichert, W.;Roeske, A.;Gekeler, V.;Beckers, T.;Stephan, C.;Jung, K.;Fritzsche, F. R.;Niesporek, S.;Denkert, C.;Dietel, M.;Kristiansen, G.

文献摘要

参考文献

被引文献

相似文献

组蛋白去乙酰化酶(HDAC)的高活性导致与恶性细胞行为相关的表观遗传学改变。因此,HDAC抑制剂已作为新药进入后期临床试验。然而,对包括前列腺癌在内的人类肿瘤中特定HDAC亚型的表达和功能知之甚少。我们通过免疫组化研究了192例前列腺癌中I类HDAC的表达,并将我们的研究结果与包括随访数据在内的临床病理参数相关联。I类HDAC亚型在大多数病例中强烈表达(HDAC 1:69.8%,HDAC 2:74%,HDAC 3:94.8%)。HDAC1和HDAC2的高表达率与肿瘤去分化显著相关。所有HDAC的强表达伴随着增强的肿瘤细胞增殖。此外,HDAC2是我们前列腺癌队列中的独立预后标志物。总之,我们表明,体外观察到的HDAC对癌细胞分化和增殖的已知作用也可以在体内得到证实。I类HDAC亚型1、2和3在前列腺癌中差异表达,这对于即将进行的关于该肿瘤实体中HDAC抑制剂的研究可能是重要的。此外,HDAC 2的高度显著的预后价值显然值得进一步研究。
High activity of histone deacetylases (HDACs) causes epigenetic alterations associated with malignant cell behaviour. Consequently, HDAC inhibitors have entered late-phase clinical trials as new antineoplastic drugs. However, little is known about expression and function of specific HDAC isoforms in human tumours including prostate cancer. We investigated the expression of class I HDACs in 192 prostate carcinomas by immunohistochemistry and correlated our findings to clinicopathological parameters including follow-up data. Class I HDAC isoforms were strongly expressed in the majority of the cases (HDAC1: 69.8%, HDAC2: 74%, HDAC3: 94.8%). High rates of HDAC1 and HDAC2 expression were significantly associated with tumour dedifferentiation. Strong expression of all HDACs was accompanied by enhanced tumour cell proliferation. In addition, HDAC2 was an independent prognostic marker in our prostate cancer cohort. In conclusion, we showed that the known effects of HDACs on differentiation and proliferation of cancer cells observed in vitro can also be confirmed in vivo. The class I HDAC isoforms 1, 2 and 3 are differentially expressed in prostate cancer, which might be important for upcoming studies on HDAC inhibitors in this tumour entity. Also, the highly significant prognostic value of HDAC2 clearly deserves further study.
DOI: 10.1038/sj.bjc.6601510
发表时间: 2004-01-26
影响因子: 8.8
作者:
Kuefer, R;Hofer, M D;Altug, V;Zorn, C;Genze, F;Kunzi-Rapp, K;Hautmann, R E;Gschwend, J E
通讯作者: Gschwend, J E
DOI: 10.1158/0008-5472.can-06-1986
发表时间: 2006-11-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Iljin, Kristiina;Wolf, Maija;Kallioniemi, Olli
通讯作者: Kallioniemi, Olli
DOI: 10.1002/cncr.20709
发表时间: 2004-12-15
期刊: CANCER
影响因子: 6.2
作者:
Takai, N;Kawamata, N;Koeffler, HP
通讯作者: Koeffler, HP
DOI: 10.1016/j.bbrc.2004.01.149
发表时间: 2004-03-19
影响因子: 3.1
作者:
Kim, SH;Ahn, S;Hong, S
通讯作者: Hong, S
DOI: 10.1002/pros.20022
发表时间: 2004-05-01
期刊: PROSTATE
影响因子: 2.8
作者:
Halkidou, K;Gaughan, L;Robson, CN
通讯作者: Robson, CN